Caris Initiates Coverage on Spectranetics (SPNC) with an Average
More News related to SPNC
- Spectranetics Names Jason Hein Senior VP, Sales, Marketing and Product Development
- ThromCat(R) XT(TM) Thrombectomy Catheter System Receives CE Mark
- Spectranetics (SPNC) Announces CE Mark Approval for ThromCatXT
- Spectranetics Receives CE Mark Approval for ThromCat(R)XT
- Spectranetics (SPNC) Reports Q1 Loss of $0.09
Caris initiates coverage on Spectranetics (Nasdaq: SPNC) with an Average. Price target $5.
The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system for use with Spectranetics' excimer laser system.
Related Categories
New CoverageStocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
